Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that AstraZeneca COVID-19 vaccine(ChAdOx1-S [Recombinant]), when given as a third dose booster, increased the immune response to Beta, Delta, Alpha and GammaSARS-CoV-2 variants, while a separate analysis of samples from the trial showed increased antibody response to the Omicron variant.
The results were observed among individuals previously vaccinated with either AstraZeneca COVID-19 vaccine or an mRNA vaccine.
A separate Phase IV trial reported in a preprint with The Lanceton SSRNshowed that a third dose of AstraZeneca COVID-19 vaccinesubstantially increased antibody levels following a primary vaccine series with CoronaVac(Sinovac Biotech).1
Sir MenePangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “AstraZeneca COVID-19 vaccinehas protected hundreds of millions of people from COVID-19 around the world and these data show that it has an important role to play as a third dose booster, including when used after other vaccines. Given the ongoing urgency of the pandemic and AstraZeneca COVID-19 vaccine’s increased immune response to the Omicron variant, we will continue to progress regulatory submissions around the world for its use as a third dose booster.”
Professor Sir Andrew J Pollard, chief investigator and director of the Oxford Vaccine Group at the University of Oxford, said: “These important studies show that a third dose of AstraZeneca COVID-19 vaccine after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, strongly boosts immunity against COVID-19. The Oxford-AstraZeneca vaccine is suitable as an option to enhance immunity in the population for countries considering booster programmes, adding to the protection already demonstrated with the first two doses.”
Sameh El Fangary, Country President, GCC & Pakistan, AstraZeneca, said: “The latest AstraZeneca COVID-19 vaccine data shows the vaccine’s efficacy as a third dose booster against all variants of concern, including when used after other vaccines. This is of a particular importance considering the spread of the Omicron variant. We are pleased to share this new data and to renew our commitment to supporting the Gulf Cooperation Council countries to safeguard the health and wellbeing of all.”
The D7220C00001 safety and immunogenicity trial showed that AstraZeneca COVID-19 vaccine continued to be generally well tolerated. Further analyses from the trial are expected in the first half of 2022.
